Nuclera

Nuclera is a biotechnology company based in Cambridge, UK, and Boston, MA, dedicated to improving human health by enhancing protein access. Founded in 2013, the company has successfully raised over £52.3 million in funding, including a recent $75 million round in October 2024. With a team of 101–250 employees, Nuclera operates within the healthcare, pharmaceutical, and biotech sectors. The company's flagship product, the eProtein Discovery™ system, automates protein prototyping workflows. This benchtop platform combines cell-free protein synthesis and digital microfluidics, allowing researchers to produce active proteins from DNA in under 48 hours. It features high-throughput screening, automated purification, and rapid protein access, making it valuable for drug discovery, structural biology, and enzyme engineering. Nuclera's innovative technology aims to replace traditional protein production methods, addressing a growing market and enhancing research efficiency. The company actively seeks partnerships to expand its applications in diagnostics and synthetic biology.